Browsing by Yonsei Author : Hong, Min Hee

eperson profile image
Name:
Hong, Min Hee [홍민희]
orcid http://orcid.org/0000-0003-3490-2195
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (57191958755)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 56

This table browses all dspace content
Issue DateTitleJournal Title
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2021Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study CANCERS
2021Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy CANCERS
2021Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors CANCERS
2021Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyCLINICAL CANCER RESEARCH
2021Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients SCIENTIFIC REPORTS
2021Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma SCIENTIFIC REPORTS
2021Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort StudyCLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
2021Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancerEUROPEAN JOURNAL OF CANCER
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2020The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma JOURNAL OF THORACIC DISEASE
2020Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCANCER
2020Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancerEXPERIMENTAL AND MOLECULAR MEDICINE
2020Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case ReportOCULAR IMMUNOLOGY AND INFLAMMATION
2020Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLCCANCER DISCOVERY
2020Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer JOURNAL FOR IMMUNOTHERAPY OF CANCER
2020Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer CLINICAL CANCER RESEARCH
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2020Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response BRITISH JOURNAL OF CANCER
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2020Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives IMMUNE NETWORK
2019Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyLANCET ONCOLOGY
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE
2019Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing PLOS ONE
2019Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma SCIENTIFIC REPORTS
2019High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma SCIENTIFIC REPORTS
2019Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung CancerINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2019Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapyLUNG CANCER
2019Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancerAnnals of Oncology
2019Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitorsCancer Chemotherapy and Pharmacology
2019A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIsLung Cancer
2019Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2019YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH
2019Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinomaLUNG CANCER
2019Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer YONSEI MEDICAL JOURNAL
2019Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection ratePLOS ONE
2018ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinomaONCOGENE
2018Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical PracticeJOURNAL OF THORACIC ONCOLOGY
2018Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.CANCER RESEARCH
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationLUNG CANCER
2018Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survivalLUNG CANCER
2018Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neckHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
2017Povidone-iodine for the management of oral mucositis during cancer therapy Oncology Reviews
2017Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization ONCOTARGET
2017Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaANNALS OF ONCOLOGY
2017Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis ONCOTARGET
2016PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients SCIENTIFIC REPORTS
2014Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneCANCER CHEMOTHERAPY AND PHARMACOLOGY
12

Browse

Links